Daniel Marti‐Morente
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel Marti‐Morente has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Carles Serra‐Pages
Immunology Service Hospital Clinic Barcelona Barcelona Spain
2 shared publications - Cristina Arnaldos-Pérez
Immunology Service Hospital Clinic Barcelona Barcelona Spain
2 shared publications - Daniel Lorca-Arce
Immunology Service Hospital Clinic Barcelona Barcelona Spain
2 shared publications - David Loli-Ausejo
Hospital Clínic de Barcelona
2 shared publications Jennifer Bolaños
Immunology Service Hospital Clinic Barcelona Barcelona Spain
2 shared publications- Joan Bartra
Hospital Clínic de Barcelona
2 shared publications
Latest Publications
- Open Access
Basal Serum Tryptase Outperforms Hereditary Alpha Tryptasemia as a Biomarker of Food Allergy Severity
- Open Access
- 18 December 2024
- Published by Wiley
REAL-LIFE INSIGHTS AND CLINICAL CHARACTERISTICS OF HEREDITARY ALPHA TRYPTASEMIA IN ANAPHYLACTIC PATIENTS
REAL-LIFE INSIGHTS AND CLINICAL CHARACTERISTICS OF HEREDITARY ALPHA TRYPTASEMIA IN ANAPHYLACTIC PATIENTSAuthors: Loli-Ausejo D1,2,4*, Gonzalez-Matamala MF1,2*, Martí D3, Ruano-Zaragoza M1,2,4, Mir-Ihara P1,2,4, Solis-Ynga K1,2, Lara R3, Bartra J1,2,4, Pascal M2,3,4**, Muñoz-Cano R 1,2,4**1. Department of Allergy, Hospital Clinic Barcelona, Universitat de Barcelona (UB), Barcelona, Spain.2. Clinical and Experimental Respiratory Immunoallergy (IRCE), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.3. Department of Immunology, Hospital Clínic Barcelona, Universitat de Barcelona (UB), Barcelona, Spain.4. Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Red de Enfermedades Inflamatorias (REI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.* Loli-Ausejo D and Gonzalez-Matamala MF contributed equally to this work** Pascal M and Muñoz-Cano R contributed equally to this workCorrespondance : rmunoz@clinic.cat
- 18 December 2024
- Published by Wiley
Open AccessREAL-LIFE INSIGHTS AND CLINICAL CHARACTERISTICS OF HEREDITARY ALPHA TRYPTASEMIA IN ANAPHYLACTIC PATIENTS
REAL-LIFE INSIGHTS AND CLINICAL CHARACTERISTICS OF HEREDITARY ALPHA TRYPTASEMIA IN ANAPHYLACTIC PATIENTSAuthors: Loli-Ausejo D1,2,4*, Gonzalez-Matamala MF1,2*, Martí D3, Ruano-Zaragoza M1,2,4, Mir-Ihara P1,2,4, Solis-Ynga K1,2, Lara R3, Bartra J1,2,4, Pascal M2,3,4**, Muñoz-Cano R 1,2,4**1. Department of Allergy, Hospital Clinic Barcelona, Universitat de Barcelona (UB), Barcelona, Spain.2. Clinical and Experimental Respiratory Immunoallergy (IRCE), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.3. Department of Immunology, Hospital Clínic Barcelona, Universitat de Barcelona (UB), Barcelona, Spain.4. Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Red de Enfermedades Inflamatorias (REI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.* Loli-Ausejo D and Gonzalez-Matamala MF contributed equally to this work** Pascal M and Muñoz-Cano R contributed equally to this workCorrespondance : rmunoz@clinic.cat
- Open Access
Identification of a new HLA‐DRB1 allele, HLA‐DRB1*04:361
A novel HLA‐DRB1*04 allele, officially designated HLA‐DRB1*04:361, was identified by next‐generation sequencing.
Open AccessIdentification of a new HLA‐DRB1 allele, HLA‐DRB1*04:361
A novel HLA‐DRB1*04 allele, officially designated HLA‐DRB1*04:361, was identified by next‐generation sequencing.
Identification of a new HLA‐B allele, HLA‐B*51:371
A novel HLA‐B*51 allele, officially designated HLA‐B*51:371, was identified by next‐generation sequencing.
Identification of a new HLA‐B allele, HLA‐B*51:371
A novel HLA‐B*51 allele, officially designated HLA‐B*51:371, was identified by next‐generation sequencing.
- Open Access
- 12 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5403
The Aryl Hydrocarbon Receptor Ligand FICZ Improves Left Ventricular Remodeling and Cardiac Function at the Onset of Pressure Overload-Induced Heart Failure in Mice
Adverse ventricular remodeling is the heart’s response to damaging stimuli and is linked to heart failure and poor prognosis. Formyl-indolo [3,2-b] carbazole (FICZ) is an endogenous ligand for the aryl hydrocarbon receptor (AhR), through which it exerts pleiotropic effects including protection against inflammation, fibrosis, and oxidative stress. We evaluated the effect of AhR activation by FICZ on the adverse ventricular remodeling that occurs in the early phase of pressure overload in the murine heart induced by transverse aortic constriction (TAC). Cardiac structure and function were evaluated by cardiac magnetic resonance imaging (CMRI) before and 3 days after Sham or TAC surgery in mice treated with FICZ or with vehicle, and cardiac tissue was used for biochemical studies. CMRI analysis revealed that FICZ improved cardiac function and attenuated cardiac hypertrophy. These beneficial effects involved the inhibition of the hypertrophic calcineurin/NFAT pathway, transcriptional reduction in pro-fibrotic genes, and antioxidant effects mediated by the NRF2/NQO1 pathway. Overall, our findings provide new insight into the role of cardiac AhR signaling in the injured heart.
- 12 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5403
Open AccessThe Aryl Hydrocarbon Receptor Ligand FICZ Improves Left Ventricular Remodeling and Cardiac Function at the Onset of Pressure Overload-Induced Heart Failure in Mice
Adverse ventricular remodeling is the heart’s response to damaging stimuli and is linked to heart failure and poor prognosis. Formyl-indolo [3,2-b] carbazole (FICZ) is an endogenous ligand for the aryl hydrocarbon receptor (AhR), through which it exerts pleiotropic effects including protection against inflammation, fibrosis, and oxidative stress. We evaluated the effect of AhR activation by FICZ on the adverse ventricular remodeling that occurs in the early phase of pressure overload in the murine heart induced by transverse aortic constriction (TAC). Cardiac structure and function were evaluated by cardiac magnetic resonance imaging (CMRI) before and 3 days after Sham or TAC surgery in mice treated with FICZ or with vehicle, and cardiac tissue was used for biochemical studies. CMRI analysis revealed that FICZ improved cardiac function and attenuated cardiac hypertrophy. These beneficial effects involved the inhibition of the hypertrophic calcineurin/NFAT pathway, transcriptional reduction in pro-fibrotic genes, and antioxidant effects mediated by the NRF2/NQO1 pathway. Overall, our findings provide new insight into the role of cardiac AhR signaling in the injured heart.